Correlation Between Structure Therapeutics and Molecular Partners
Can any of the company-specific risk be diversified away by investing in both Structure Therapeutics and Molecular Partners at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Structure Therapeutics and Molecular Partners into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Structure Therapeutics American and Molecular Partners AG, you can compare the effects of market volatilities on Structure Therapeutics and Molecular Partners and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Structure Therapeutics with a short position of Molecular Partners. Check out your portfolio center. Please also check ongoing floating volatility patterns of Structure Therapeutics and Molecular Partners.
Diversification Opportunities for Structure Therapeutics and Molecular Partners
-0.22 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Structure and Molecular is -0.22. Overlapping area represents the amount of risk that can be diversified away by holding Structure Therapeutics America and Molecular Partners AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Molecular Partners and Structure Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Structure Therapeutics American are associated (or correlated) with Molecular Partners. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Molecular Partners has no effect on the direction of Structure Therapeutics i.e., Structure Therapeutics and Molecular Partners go up and down completely randomly.
Pair Corralation between Structure Therapeutics and Molecular Partners
Given the investment horizon of 90 days Structure Therapeutics American is expected to under-perform the Molecular Partners. But the stock apears to be less risky and, when comparing its historical volatility, Structure Therapeutics American is 1.15 times less risky than Molecular Partners. The stock trades about 0.0 of its potential returns per unit of risk. The Molecular Partners AG is currently generating about 0.05 of returns per unit of risk over similar time horizon. If you would invest 420.00 in Molecular Partners AG on August 26, 2024 and sell it today you would earn a total of 109.00 from holding Molecular Partners AG or generate 25.95% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Structure Therapeutics America vs. Molecular Partners AG
Performance |
| Timeline |
| Structure Therapeutics |
| Molecular Partners |
Structure Therapeutics and Molecular Partners Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Structure Therapeutics and Molecular Partners
The main advantage of trading using opposite Structure Therapeutics and Molecular Partners positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Structure Therapeutics position performs unexpectedly, Molecular Partners can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Molecular Partners will offset losses from the drop in Molecular Partners' long position.| Structure Therapeutics vs. Day One Biopharmaceuticals | Structure Therapeutics vs. X4 Pharmaceuticals | Structure Therapeutics vs. Inozyme Pharma | Structure Therapeutics vs. Acumen Pharmaceuticals |
| Molecular Partners vs. Eliem Therapeutics | Molecular Partners vs. HCW Biologics | Molecular Partners vs. Scpharmaceuticals | Molecular Partners vs. Milestone Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Other Complementary Tools
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |